Circulation · 2002 · 490 citations · 11 references
MedicineCardiologyBone MetabolismInflammationRisk Factor AnalysisCardiac BiomarkersCardiovascular DiseaseCardiovascular RiskCoronary Artery DiseaseIschemic Heart DiseaseAtherosclerotic Risk AssessmentCoronary Heart Disease EpidemiologyOsteoprotegerin DysregulationOsteoprotegerin RegulationOsteoprotegerin Signaling
BACKGROUND: Osteoprotegerin (OPG) is a secretory glycoprotein that belongs to the tumor necrosis factor receptor family. OPG-deficient mice develop severe osteoporosis and medial arterial calcification of the aorta and renal arteries. OPG immunoreactivity was demonstrated in the normal blood vessels and in early atherosclerotic lesions. A recent clinical study suggests that there is a significant correlation between elevated serum OPG levels and cardiovascular mortality. We examined whether serum OPG levels are associated with the progression of coronary artery disease (CAD). METHODS AND RESULTS: Serum OPG levels were examined in 201 patients who underwent coronary angiography because of stable chest pain. The number of diseased vessels was used to represent the severity of CAD. Serum OPG levels were measured by ELISA and were significantly greater in patients with significant stenosis of the coronary arteries than in those without stenosis. As the severity of CAD increased, there was a significant increase in serum OPG levels. Serum OPG levels were 0.94+/-0.34, 1.04+/-0.38, 1.19+/-0.38, and 1.44+/-0.54 ng/mL (medians 0.91, 0.99, 1.09, and 1.37) for the subjects with normal coronary arteries or luminal irregularities, 1-vessel disease, 2-vessel disease, and 3-vessel disease, respectively. Multivariate logistic regression analysis revealed that serum OPG levels were significantly associated with the presence of CAD [odds ratio, 5.2; 95% confidence interval, 1.7 to 16.0]. CONCLUSIONS: Our data show that serum OPG levels are associated with the presence and severity of CAD, suggesting that OPG may be involved in the progression of CAD.
11
Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density
W. Scott Simonet, Dave Lacey, Colin R. Dunstan et al. · Cell · 1997 · 5.1K citations · Full text
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
Young‐Yun Kong, Hiroki Yoshida, Ildiko Sarosi et al. · Nature · 1999 · 3.4K citations
Medicine, Cell Biology, Immunology +14
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
John G. Emery, Peter McDonnell, Michael Brigham Burke et al. · Journal of Biological Chemistry · 1998 · 1.2K citations · Full text